TABLE 4.
Primary and secondary outcomes with different drug regimens
| COVID drug | QTc ≥ 500 ms | ∆QTc ≥ 60 ms | TdP |
|---|---|---|---|
| Chloroquine (n = 9) | 0 | 3 (33.0) | 0 |
| Chloroquine (n = 6) | 0 | 2 (33.0) | 0 |
| Chloroquine + Azithromycin (n = 3) | 0 | 1 (33.0) | 0 |
| Hydroxychloroquine (n = 1430) | 196 (13.7) | 300 (21.0) | 4 (0.3) |
| Hydroxychloroquine monotherapy (n = 350) | 41 (11.7) | 63 (18.0) | 0 |
| Hydroxychloroquine + Azithromycin (n = 1080) | 155 (14.4) | 237 (22.0) | 4 (0.4) |
| Lopinavir/ritonavir (n = 689) | 52 (7.5) | 90 (13.0) | 5 (0.78) |
| Lopinavir/ritonavir (n = 483) | 27 (5.6) | 38 (8.0) | 0 |
| Lopinavir/ritonavir + Azithromycin (n = 206) | 25 (12.0) | 52 (25.0) | 5 (2.4) |
| Atazanavir/ritonavir (n = 16) | 3 (18.7) | 2 (12.5) | 0 |
| Atazanavir/ritonavir (n = 12) | 2 (16.7) | 1 (8.3) | 0 |
| Atazanavir/ritonavir + Azithromycin (n = 4) | 1 (25) | 1 (25) | 0 |
| Oseltamivir (n = 121) | 8 (6.6) | 13 (10.7) | 0 |
| Oseltamivir (n = 18) | 0 | 3 (16.7) | 0 |
| Oseltamivir + Azithromycin (n = 103) | 8 (7.8) | 10 (9.7) | 0 |
| Favipiravir (n = 33) | 1 (3.0) | 3 (9.0) | 0 |
| Remdesivir (n = 67) | 6 (9.0) | 6 (9.0) | 0 |
Variables are presented as n (%).